How to Sell to Pharmaceutical Manufacturers in Europe

To sell to pharmaceutical manufacturers, pick the manufacturing sites you can actually serve. Then reach the people who own your problem inside each plant, usually engineering, quality assurance (QA), validation or the site head. Procurement tends to join later, once the technical side wants you.

Good manufacturing practice (GMP) is the reason. Under GMP, a new supplier is a controlled change that has to be assessed, qualified and documented before anything is ordered. So the first thing you sell is your fitness to be approved.

That makes the unit of sale a site. A group with nine plants is nine accounts, each with its own quality team, its own inspections and its own priorities. The plant commissioning a new filling line and the plant still closing out findings from its last inspection want very different conversations, even under the same logo.

This guide covers the plants that make medicines and their ingredients in the UK and Europe, and the suppliers who sell to them: process equipment, cleanroom and contamination-control services, validation, lab and quality control (QC) services, packaging, software and logistics. Selling finished medicines to hospitals and the NHS, and US FDA rules, involve separate buyers with separate processes, so they are left out on purpose.

The order I use for any market is: who already paid you, who signed, whether the market can feed a campaign, which geography, and only then the channel and the wording. The general version of that sequence is in how I choose a market before any outreach goes out.

Who actually buys at a pharmaceutical manufacturing site?

A small group of functions inside the plant, each owning one part of the decision. No single title decides alone everywhere. Who holds the pen depends on the size of the purchase, whether it can touch the product, and how much power the company keeps at head office.

Two rows confuse outsiders. In many plants, validation sits apart from QA, and it decides how much testing and paperwork your product will cost the site. The Qualified Person carries a legal responsibility for the batches leaving the plant, whatever their place on the org chart.

For outreach, the table collapses into four owners:

• Economic owner. The site head, or a group-level engineering or operations leader on large capital projects. Decides whether money gets spent this year.
• Technical owner. Engineering, validation or the QC lab, depending on what you sell. Decides whether your product fits.
• Workflow owner. Production and QA, who live with the change after approval. Decides how much friction it creates.
• Purchasing owner. Site or category procurement. Decides terms and runs onboarding.

Your first message goes to the technical owner, or to QA when your product needs supplier approval before anyone can test it. A vendor who opens with procurement is asking a buyer to champion a problem that belongs to somebody else.

Before my team builds a single list, I go back through a client's closed projects and find out who really made the decision in each one. Then we search for the titles that niche actually uses, instead of whatever sounds senior in a lead tool. In a plant, that exercise may show a validation lead or an engineering manager behind deals the org chart would credit to someone far higher.

Why are pharma supplier changes so slow?

Because GMP turns a purchase into a change to a controlled system, and changes have a procedure long before they have a budget.

The UK regulator is direct about it. The MHRA's GMP guidance describes GMP as the lowest bar a medicines manufacturer has to clear in production, and says sites are inspected when they apply for a licence and after that at intervals set by risk. Findings are graded critical, major or other, and the manufacturer cannot appeal the grade.

For a QA director, every new supplier is one more thing an inspector can ask about, and a graded finding stays on the record. Switching without a strong reason is risk with no upside, which is why a decent incumbent is so hard to move.

Here is roughly what a plant works through before your product reaches routine use. Names and order vary by company:

1. Someone raises a change request explaining why the current supplier or method falls short.
2. QA assesses the risk: can this affect the product, the batch record or the clean environment?
3. You get qualified as a supplier through a questionnaire, a document review and sometimes an audit.
4. Equipment and computerized systems get validated, meaning tested and documented to show they do what they claim.
5. Procedures, training records and the approved supplier list get updated.
6. QA closes the change, and only then does regular buying start.

The EU rulebook shows the same thing in its structure. EudraLex Volume 4, the EU GMP guidelines, has Part I chapters on the pharmaceutical quality system, documentation, production and outsourced activities. If you run a contract lab or a validation service, your work falls under the outsourced activities chapter, so the site will want to see your quality system before it looks at your price.

Two annexes add weight for specific sellers. Annex 1 covers the manufacture of sterile medicinal products. The revised version came into operation on 25 August 2023 and has been fully applicable since 25 August 2024, when its last postponed point took effect. If what you sell enters a cleanroom, an aseptic filling area or the site's contamination control, expect it to be judged against that annex, with more documents and more people involved.

Annex 16 sets the rules for how the Qualified Person certifies and releases each batch. Any product or service that can change a batch has to leave the QP comfortable certifying batches made with it.

Decision rule: if your offer touches the product, the batch record or the clean environment, expect change control and bring your qualification pack to the first serious call. If it touches none of those, such as office furniture or canteen services, you are selling to facilities and procurement as you would at any other factory.

What should you sell to pharma manufacturers first?

The offer that solves one problem the site already knows it has. Here is how the main supplier categories map onto plant problems:

A broad offer such as "validation services for life sciences" is easy to ignore. It names a category, and every site already has a supplier for that category. Name the plant type, the problem and the moment instead: "extra validation engineers for UK sterile sites with a new line to qualify this year."

For software vendors, the same test sets the route. If your software touches validation, quality records or batch release, sell it through the quality and validation path. Validation or QA comes first, IT evaluates, procurement comes last. If it never touches GMP data, IT and procurement can buy it like any other factory software.

How big is the UK opportunity right now?

Small next to most outbound markets, and the count shapes the plan.

The UK's bioscience and health technology sector statistics count 7,320 life sciences companies in 2023 to 2024, owned by 6,170 businesses (a business being the group that owns one or more companies), employing 359,600 people with £146.9 billion in turnover. The release came out in October 2025 as official statistics in development.

Biopharmaceutical companies made up 40% of the total, 2,960 companies, and 67% of turnover. A quarter of all life sciences companies, 1,860, named manufacturing as their main activity, but only 16% of biopharmaceutical companies did.

Do the sum. 16% of 2,960 is about 470 biopharmaceutical companies whose main activity is manufacturing. The release counts registered companies, not plants, so the sites you can actually serve still have to be listed one by one, and that site count, not the headline, sets how many people are worth contacting.

The Life Sciences Sector Plan puts up to £520 million behind manufacturing through its Life Sciences Innovative Manufacturing Fund.

Funded manufacturing investment turns into projects: new lines, more capacity, upgraded facilities. Each one needs equipment, cleanroom work, qualification, QC capacity and, later, packaging and logistics.

For a supplier, a site that is building something is already running change control on dozens of items, so adding yours costs it less than at a plant where nothing has changed for years. Put expanding sites at the top of your list and steady-state sites into a slower, longer sequence.

The EU works under the same logic. According to the European Commission, making or importing medicines there requires a manufacturing or import authorisation, and the holder must follow GMP. The plants you target in Ireland, Germany or Italy therefore run the same change control described above. For each EU country you target, build the same count from your own data before you plan any volume.

How do you build the right target list?

Start from the sites you can serve, then count them.

1. Your own clients first. I begin every list with past and current clients, then look for plants that resemble them in size, production type and problem.
2. Site filters. Country, site type (sterile, oral solid dose, biologics, active ingredients, packaging-only, contract manufacturer) and production scale. Each plant gets its own row, even inside one group.
3. Real titles only. Pull them from the buyer map above. Assistant, associate and a bare "manager" come off every list my team builds. "Validation Manager" stays. "Manager" with no function goes.
4. Exclusions. Commercial, marketing, medical affairs and field sales people work for the brand, so leave them out.
5. Count. Sites x real buyers per site = your market. Write that number down before you decide on volume.

The count usually changes the plan. A UK pharma manufacturing list is small, so the plan trades width for depth: more functions per site, longer sequences, more patience and often a second country.

My team uses intent data when the total market is large; in a small one, such as 2,000 target companies with intent signals on about 10 of them, we skip it and write an offer the whole market can use. A UK list built from roughly 470 biopharmaceutical manufacturing companies is far closer to that small case, so the offer has to do the work.

Should you start with cold email or LinkedIn?

LinkedIn first in almost every case, email behind it, and in three countries LinkedIn on its own.

The reasoning behind each row:

• Email comes second. On a cold account, LinkedIn opens and the email picks up a conversation that has already started. Site people are not on LinkedIn all day, so the email is what catches them at their desk.
• Germany, Austria and the Czech Republic. My team does not cold email these markets without a compliant basis and uses LinkedIn there instead; Germany is not a market we specialize in, and when a client needs it we apply stricter rules of our own. This is not legal advice.
• The UK and English-speaking targets. Run LinkedIn and email as one sequence across both channels. The wiring is in building a follow-up sequence across LinkedIn and email.
• Opt-outs. When someone asks my team not to contact them again, they go on an exclusion list and stay off every later campaign.

For the wider country picture, see country rules for outbound into Europe.

Set the target as conversations. Calls come out of conversations and contracts come out of calls, so in a slow market measure that first stage first.

What should the first message say to a pharma manufacturer?

One site problem, one line of proof, one small ask.

In the first message I sell a conversation and keep the service for the call. A pitch in message one is the quickest route to silence. To a QA lead, a feature list mostly reads as one more thing to qualify.

Build it in this order:

1. The site's situation. One sentence about this plant: its production type, an announced expansion, a new line. Never "pharma companies like yours".
2. Proof from your own work. Put a past client, a result or a case study inside the message itself, chosen for this function.
3. A small ask. A 15-minute call, or permission to send the one document that answers their first qualification question.

Keep it short and write it the way you would write to one engineer you know.

The reason to reply changes by function:

Before anyone replies, they look you up, so a large part of the sale happens on your profile and website before any call. Once replies arrive, decide who earns a slot using the checks to run on a reply before the calendar link goes out.

What does a realistic first 30 days look like?

A plant will talk to you within weeks and sign within quarters. Before launch, set expectations that B2B deals often take 6, 9 or 12 months and that calls booked in month one may turn into contracts 4 or more months later. So do not judge outbound on the first invoice. In pharma, add the qualification steps above on top of that.

Plan for at least 3 months of outbound so there is time to get feedback and adjust. The industry average to get it fully working is about 6 months.

• Week 1. Build and count the site list, and fix the LinkedIn profiles of everyone who will send messages. If you plan to email UK sites, set up new sending accounts now, because they need time to warm up.
• Week 2. Start LinkedIn connection requests with a note, technical owners first.
• Week 3. Warm emails go to accepted connections. Raise volume only after warm-up is finished.
• Week 4. Follow-ups, with real gaps between touches. Sort every reply by function: which roles answer, and which objections repeat.

Judge month one on conversations started with the right functions and on how many replies come from technical owners.

If the list is too small or the message too broad, more volume will not fix it. A small test that draws nothing from the right functions will not improve at ten times the size, so fix the offer and the list first and scale after.

What changes if you sell validation software?

Sell it as lower quality risk. Validation teams buy fewer documentation gaps, faster reviews and evidence they can put in front of an inspector.

The buying path is the quality and validation route from the offer section, with engineering joining when the software touches equipment and the site head signing on larger projects. Write to the validation lead about their backlog and their next inspection, and show a site like theirs before and after, measured in documents and review time.

Validation leads and their QA director look up whoever messages them, so fix the profiles of everybody involved in the sale, including the solution engineer who will run the demo. Posts about validation problems help people recognize your name, but the deals come out of direct conversations.

If you sell to pharma manufacturing sites and want help mapping who buys at each plant, book a call with me and we can start with one site.